| | 27262-47-1 Basic information More.. |
| Product Name: | Levobupivacaine | | Synonyms: | 1-Butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide;Chirocaine;Levobupivacaine;(2S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2α-carboxamide;2',6'-Pipecoloxylidide, 1-butyl-, L-(-)-;1-Butyl-N-(2,6-dimet;Levobupivacaine base;(2S)-1-Butyl-N-(2,6-diMethylphenyl)-2-piperidinecarboxaMide | | CAS: | 27262-47-1 | | MF: | C18H28N2O | | MW: | 288.43 | | EINECS: | 1533716-785-6 | | Mol File: | 27262-47-1.mol |  |
Use
Levobupivacaine is the pure “S” enantiomer of bupivacaineand in vivo and in vitro studies confirm that it does notundergo metabolic inversion to R(+) bupivacaine. The pKaof the tertiary nitrogen is 8.09, the same as bupivacaine’s pKa. Levobupivacaine is available in solution for epiduraladministration, peripheral nerve block administration, andinfiltration anesthesia. Clinical trials have shown thatlevobupivacaine and bupivacaine have similar anestheticeffects. Levobupivacaine has lower CNS and cardiotoxicitythan bupivacaine although unintended intravenousinjection when performing nerve blocks may result intoxicity. Racemic bupivacaine is metabolized extensivelywith no unchanged drug found in the urine or feces. Liverenzymes including the CYP3A4 and CYP1A2 isoforms areresponsible for N-dealkylation and 3-hydroxylation oflevobupivacaine followed by glucuronidation or sulfation.
- Levobupivacaine
-
- US $1.00 / g
- 2024-08-23
- CAS:27262-47-1
- Min. Order: 1g
- Purity: 0.98
- Supply Ability: 1000
- Levobupivacaine
-
- US $3.00-1.00 / kg
- 2024-04-12
- CAS:27262-47-1
- Min. Order: 1kg
- Purity: 99.9%
- Supply Ability: 10 tons
- Levobupivacaine
-
- US $45.00-35.00 / kg
- 2024-02-21
- CAS:27262-47-1
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
|
|
27262-47-1
Recommend Suppliers |
|